PL3157933T3 - Synteza policyklicznych związków karbamoilopirydonowych - Google Patents

Synteza policyklicznych związków karbamoilopirydonowych

Info

Publication number
PL3157933T3
PL3157933T3 PL15739049T PL15739049T PL3157933T3 PL 3157933 T3 PL3157933 T3 PL 3157933T3 PL 15739049 T PL15739049 T PL 15739049T PL 15739049 T PL15739049 T PL 15739049T PL 3157933 T3 PL3157933 T3 PL 3157933T3
Authority
PL
Poland
Prior art keywords
polycyclic
synthesis
carbamoylpyridone compounds
carbamoylpyridone
compounds
Prior art date
Application number
PL15739049T
Other languages
English (en)
Inventor
Anna Chiu
John ENQUIST
Nolan GRIGGS
Christopher Hale
Norihiro Ikemoto
Katie Ann Keaton
Matt KRAFT
Scott E. Lazerwith
Michel LEEMAN
Zhihui Peng
Kate SCHRIER
Jonathan TRINIDAD
Jochem Van Herpt
Andrew W. Waltman
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3157933T3 publication Critical patent/PL3157933T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL15739049T 2014-06-20 2015-06-16 Synteza policyklicznych związków karbamoilopirydonowych PL3157933T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015081P 2014-06-20 2014-06-20
PCT/US2015/036017 WO2015195656A2 (en) 2014-06-20 2015-06-16 Synthesis of polycyclic-carbamoylpyridone compounds
EP15739049.3A EP3157933B1 (en) 2014-06-20 2015-06-16 Synthesis of polycyclic-carbamoylpyridone compounds

Publications (1)

Publication Number Publication Date
PL3157933T3 true PL3157933T3 (pl) 2019-09-30

Family

ID=53674256

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15739049T PL3157933T3 (pl) 2014-06-20 2015-06-16 Synteza policyklicznych związków karbamoilopirydonowych
PL19152851T PL3527573T3 (pl) 2014-06-20 2015-06-16 Synteza policyklicznych związków karbamoilopirydonowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19152851T PL3527573T3 (pl) 2014-06-20 2015-06-16 Synteza policyklicznych związków karbamoilopirydonowych

Country Status (21)

Country Link
US (3) US20150368264A1 (pl)
EP (3) EP3783001A1 (pl)
JP (2) JP6581607B2 (pl)
KR (2) KR101975912B1 (pl)
CN (3) CN114394983A (pl)
AR (2) AR100904A1 (pl)
AU (3) AU2015277312B2 (pl)
BR (2) BR122021009062B1 (pl)
CA (2) CA2950300C (pl)
EA (2) EA034169B1 (pl)
ES (2) ES2718409T3 (pl)
IL (3) IL249134B (pl)
MX (2) MX363532B (pl)
NZ (1) NZ726859A (pl)
PL (2) PL3157933T3 (pl)
PT (2) PT3527573T (pl)
SG (2) SG11201609945SA (pl)
SI (2) SI3527573T1 (pl)
TR (1) TR201906366T4 (pl)
TW (2) TWI744723B (pl)
WO (1) WO2015195656A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344879B (es) 2012-12-21 2017-01-11 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
WO2015110897A2 (en) 2014-01-21 2015-07-30 Laurus Labs Private Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
NO2717902T3 (pl) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
KR102606625B1 (ko) 2015-11-09 2023-11-27 길리애드 사이언시즈, 인코포레이티드 인간 면역결핍 바이러스의 치료를 위한 치료 조성물
ZA201803942B (en) 2017-06-13 2021-05-26 Cipla Ltd Novel processes for preparation of integrase inhibitor
CN109020911B (zh) * 2018-04-16 2022-06-28 常州制药厂有限公司 用于制备bictegravir的中间体及其制备方法
CN108774145A (zh) * 2018-05-23 2018-11-09 安徽华昌高科药业有限公司 一种(1r,3s)-3-氨基环戊醇盐酸盐的制备方法
WO2020003151A1 (en) 2018-06-28 2020-01-02 Honour Lab Limited Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1', 2':4,5]pyrazino[2,1-b] [1,3] oxazepin-8-olate and its polymorphic form
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
CN110862325B (zh) * 2018-08-28 2020-08-25 重庆博腾制药科技股份有限公司 一种(1r,3s)-3-氨基-1-环戊醇及其盐的制备方法
CN111018725B (zh) * 2018-10-09 2023-07-07 上海迪赛诺化学制药有限公司 一种（1r,3s）-3-氨基环戊醇手性酸盐的制备方法
US11603523B2 (en) 2019-01-18 2023-03-14 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN109868293A (zh) * 2019-01-22 2019-06-11 湖南理工学院 一种酶催化酯交换动力学拆分2-氯扁桃酸对映体的方法
CN110041210A (zh) * 2019-05-06 2019-07-23 凯瑞斯德生化(苏州)有限公司 一种Bictegravir中间体及其制备方法
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CN111056939B (zh) * 2019-10-16 2022-08-05 弈柯莱生物科技(上海)股份有限公司 一种(1r,3s)-3-氨基环戊醇及其中间体的制备方法
CN112174929A (zh) * 2020-10-13 2021-01-05 台州市生物医化产业研究院有限公司 一种西他列汀关键中间体热解杂质及其制备方法和应用
US20250296933A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788516A (fr) 1971-09-10 1973-03-07 Lonza Ag Procede de fabrication d'esters alcoxyacetylacetiques
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4575694A (en) 1984-03-05 1986-03-11 Allied Corporation Coaxial connector
GB8729994D0 (en) 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
DE3900735A1 (de) * 1989-01-12 1990-07-26 Hoechst Ag Neue mehrfunktionelle (alpha)-diazo-(beta)-ketoester, verfahren zu ihrer herstellung und deren verwendung
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
DE4014649A1 (de) * 1990-05-08 1991-11-14 Hoechst Ag Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
FR2734822B1 (fr) 1995-05-30 1997-07-04 Rhone Poulenc Rorer Sa Nouveaux derives du 2-azabicyclo(2.2.1)heptane, leur preparation et leur application
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
CA2285548C (en) 1997-04-04 2006-07-11 Pfizer Products Inc. Nicotinamide derivatives
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
WO1999025345A1 (en) * 1997-11-14 1999-05-27 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
EP1178969B1 (en) * 1998-11-09 2005-07-13 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
NZ512184A (en) 1998-12-25 2003-08-29 Shionogi & Co Aromatic heterocycle compounds having HIV integrase inhibiting activities
EP1297834A4 (en) 2000-06-14 2007-05-09 Shionogi & Co ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS
HUP0301431A2 (hu) 2000-07-27 2003-08-28 F. Hoffmann-La Roche Ag. 3-Indolil-4-fenil-1H-pirrol-2,5-dion-származékok, mint glikogén szintáz kináz-3béta inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
WO2003016275A1 (fr) 2001-08-10 2003-02-27 Shionogi & Co., Ltd. Agent antiviral
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
CZ2004442A3 (cs) 2001-10-03 2005-03-16 Ucb, S.A. Pyrrolidinonové deriváty
EP1441735B1 (en) 2001-10-26 2006-02-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
AU2003267098B2 (en) 2002-09-11 2008-11-20 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
EP1558243A4 (en) 2002-10-30 2006-11-02 Merck & Co Inc TETRAHYDROPYRANYL CYCLOPENTYL BENZYLAMIDE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
SI1564210T1 (sl) 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
JP4996241B2 (ja) 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド 組み合わせ抗ウイルス治療のための組成物および方法
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
CA2554120A1 (en) 2004-01-30 2005-08-18 Merck & Co., Inc. N-benzyl-3,4-dihydroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integras inhibitors
EP1725535A4 (en) 2004-03-09 2009-11-25 Merck & Co Inc HIV integrase
WO2005110399A2 (en) 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
WO2006028523A2 (en) 2004-04-29 2006-03-16 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO USDC Technology Transfer Office Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
US7538112B2 (en) 2004-05-07 2009-05-26 Merck & Co., Inc. HIV integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
WO2006030807A1 (ja) 2004-09-15 2006-03-23 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
JP2006118669A (ja) 2004-10-25 2006-05-11 Sanoh Industrial Co Ltd 樹脂チューブ
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
JP5317257B2 (ja) 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
US8129385B2 (en) * 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
AU2006272521A1 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EA018544B1 (ru) 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Способ лечения ретровирусной инфекции
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
JP2009525261A (ja) 2006-02-01 2009-07-09 日本たばこ産業株式会社 レトロウイルス感染症の治療のための、６−（３−クロロ−２−フルオロベンジル）−１−［（２ｓ）−１−ヒドロキシ−３−メチルブタン−２−イル］−７−メトキシ−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸またはその塩の使用
WO2007099385A1 (en) 2006-03-01 2007-09-07 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase iv inhibitor compounds and compositions
CN101437801B (zh) 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
MX2008011457A (es) 2006-03-06 2008-09-24 Japan Tobacco Inc Metodo para producir un compuesto de 4-oxoquinolina.
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2007275805A1 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
CN105503721A (zh) 2006-09-12 2016-04-20 吉里德科学公司 制备整合酶抑制剂的方法和中间体
JP2010506913A (ja) 2006-10-18 2010-03-04 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害剤
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
EP2118082B1 (en) 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US20080280945A1 (en) 2007-05-09 2008-11-13 Sachin Lohani Crystalline forms of an HIV integrase inhibitor
AU2008270634B2 (en) 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
CA2692101A1 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism
EP2182801A4 (en) 2007-07-31 2011-04-13 Limerick Biopharma Inc COMPOSITIONS OF PYRONE ANALOGS AND METHODS
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
MX2010011591A (es) * 2008-04-22 2010-11-09 Astrazeneca Ab Pirimidin-5-carboxamidas sustituidas 281.
WO2010011813A1 (en) 2008-07-23 2010-01-28 Alkermes, Inc. Complex of trospium and pharmaceutical compositions thereof
SG192550A1 (en) 2008-07-25 2013-08-30 Viiv Healthcare Co Chemical compounds
US8183372B2 (en) 2008-07-25 2012-05-22 Shionogi & Co., Ltd. Substituted 9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydor-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazines
ES2448766T3 (es) 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2376080B1 (en) 2008-12-11 2017-09-13 Shionogi&Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
EP2376453B1 (en) * 2008-12-11 2019-11-20 VIIV Healthcare Company Intermediates for carbamoylpyridone hiv integrase inhibitors
JP5697163B2 (ja) 2009-03-26 2015-04-08 塩野義製薬株式会社 置換された３−ヒドロキシ−４−ピリドン誘導体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
RS57244B1 (sr) 2009-06-15 2018-07-31 Shionogi & Co Supstituisani policiklički derivati karbamoilpiridona
KR101280198B1 (ko) * 2009-09-02 2013-06-28 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
PH12012501689A1 (en) 2010-02-26 2012-11-05 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv intergrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
ES2608377T3 (es) * 2010-08-05 2017-04-10 Shionogi & Co., Ltd. Procedimiento de preparación de un compuesto que tiene actividad inhibidora de la integrasa del HIV
CN103228653B (zh) 2010-09-24 2016-03-16 盐野义制药株式会社 被取代的多环性氨基甲酰基吡啶酮衍生物的前药
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
US9121496B2 (en) 2011-06-29 2015-09-01 Arvinmeritor Technology, Llc Drive axle system and a method of control
EP2742051B1 (en) 2011-09-14 2016-10-12 Mapi Pharma Limited Amorpous form of the dolutegravir sodium salt
US9246434B2 (en) 2011-09-26 2016-01-26 First Solar, Inc System and method for estimating the short circuit current of a solar device
BR112014008896A2 (pt) 2011-10-12 2017-04-18 Shionogi & Co derivado de piridona policíclico tendo atividade inibidora de integrase
ES2650915T3 (es) * 2011-12-12 2018-01-23 Bayer Intellectual Property Gmbh Imidazopiridazinas amino-sustituidas
KR101699822B1 (ko) 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
US20150166520A1 (en) 2012-07-20 2015-06-18 Merck Sharp & Dohme Corp. Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
US20150218164A1 (en) 2012-07-25 2015-08-06 Merck Sharp & Dohme Corp. Substituted naphthyridinedione derivatives as hiv integrase inhibitors
US8877931B2 (en) 2012-08-03 2014-11-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
PE20150953A1 (es) * 2012-11-08 2015-06-20 Bristol Myers Squibb Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
SG11201503807TA (en) 2012-12-14 2015-06-29 Glaxosmithkline Llc Pharmaceutical compositions
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX344879B (es) * 2012-12-21 2017-01-11 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
US20160000721A1 (en) 2012-12-21 2016-01-07 Merck Sharp & Dohme Corp. Gastro-retentive formulations
RU2015131006A (ru) 2012-12-27 2017-01-30 Джапан Тобакко Инк. ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ)
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
LT3019503T (lt) 2013-07-12 2017-11-27 Gilead Sciences, Inc. Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX367057B (es) 2013-09-27 2019-08-02 Merck Sharp & Dohme Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih.
WO2015076492A1 (ko) 2013-11-25 2015-05-28 주식회사 케이티 홈 네트워크 전송 선로의 간섭 완화 장치, 간섭 완화 방법 및 이를 이용한 통신 시스템
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015110897A2 (en) 2014-01-21 2015-07-30 Laurus Labs Private Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
NO2717902T3 (pl) 2014-06-20 2018-06-23
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide

Also Published As

Publication number Publication date
US20200223866A1 (en) 2020-07-16
MX2016016065A (es) 2017-03-28
TW201613853A (en) 2016-04-16
CA2950300C (en) 2019-12-24
US20180022757A1 (en) 2018-01-25
EP3157933A2 (en) 2017-04-26
TR201906366T4 (tr) 2019-05-21
US10975096B2 (en) 2021-04-13
US20150368264A1 (en) 2015-12-24
IL249134A0 (en) 2017-01-31
PT3157933T (pt) 2019-05-31
SG10201912040RA (en) 2020-02-27
IL273230A (en) 2020-04-30
KR20190049937A (ko) 2019-05-09
EP3527573B9 (en) 2022-07-06
CA3059135C (en) 2023-12-05
KR102159892B1 (ko) 2020-09-25
CN106470975B (zh) 2019-04-26
PL3527573T3 (pl) 2020-12-28
TW202014400A (zh) 2020-04-16
MX363532B (es) 2019-03-27
CN110317212B (zh) 2022-10-21
EA201992183A2 (ru) 2020-01-16
CN106470975A (zh) 2017-03-01
CA2950300A1 (en) 2015-12-23
AU2018217236A1 (en) 2018-08-30
BR112016029333B1 (pt) 2023-03-28
AU2020201369A1 (en) 2020-03-12
JP6880127B2 (ja) 2021-06-02
AU2018217236B2 (en) 2020-03-05
SI3527573T1 (sl) 2020-10-30
WO2015195656A2 (en) 2015-12-23
KR101975912B1 (ko) 2019-05-09
JP2019218391A (ja) 2019-12-26
KR20170018063A (ko) 2017-02-15
EA201692412A1 (ru) 2017-06-30
BR122021009062B1 (pt) 2022-10-11
PT3527573T (pt) 2020-10-07
MX2020001278A (es) 2020-03-12
TWI677489B (zh) 2019-11-21
ES2821143T3 (es) 2021-04-23
TWI744723B (zh) 2021-11-01
NZ736697A (en) 2023-08-25
AR132627A2 (es) 2025-07-16
IL260675B (en) 2020-03-31
JP2017521398A (ja) 2017-08-03
AR100904A1 (es) 2016-11-09
EA034169B1 (ru) 2020-01-14
SI3157933T1 (sl) 2019-05-31
ES2718409T3 (es) 2019-07-01
NZ726859A (en) 2017-12-22
EA201992183A3 (ru) 2020-04-30
SG11201609945SA (en) 2017-01-27
AU2015277312B2 (en) 2018-08-30
BR112016029333A2 (pt) 2017-08-22
JP6581607B2 (ja) 2019-09-25
WO2015195656A3 (en) 2016-03-24
EP3527573A1 (en) 2019-08-21
CA3059135A1 (en) 2015-12-23
IL249134B (en) 2018-08-30
ES2821143T9 (es) 2022-10-11
EP3527573B1 (en) 2020-08-12
CN110317212A (zh) 2019-10-11
US10519168B2 (en) 2019-12-31
AU2015277312A1 (en) 2016-12-15
EP3157933B1 (en) 2019-02-27
EP3783001A1 (en) 2021-02-24
CN114394983A (zh) 2022-04-26

Similar Documents

Publication Publication Date Title
IL273230A (en) Preparation of carbamoylpyridone-polycyclic compounds
IL255817A (en) Synthesis of heterocyclic compounds
ZA201701246B (en) Synthesis of dna
ZA201700880B (en) Polymorphs of selinexor
GB201416754D0 (en) Novel compounds
GB201417011D0 (en) Novel compounds
GB201405991D0 (en) Novel compounds
GB201417018D0 (en) Novel compounds
AP2016009432A0 (en) Novel compounds
GB201411236D0 (en) Novel compounds
GB201411239D0 (en) Novel compounds
GB201404002D0 (en) Novel compounds
IL258408B (en) Improved synthesis of honokiol
GB201512678D0 (en) Methods of chemical synthesis
PL3174849T3 (pl) Synteza pochodnych pirolidyny
HK40066086A (zh) 多环氨基甲醯基吡啶酮化合物的合成
GB201416951D0 (en) Method of synthesis
GB201408729D0 (en) Synthesis
SG11201605485QA (en) Synthesis method of 9-allylcamptothecin derivatives
GB201417021D0 (en) Novel compounds
GB201417041D0 (en) Novel compounds
GB201414614D0 (en) Novel compounds
GB201413451D0 (en) Novel compounds
GB201413260D0 (en) Novel compounds
GB201412689D0 (en) Novel compounds